Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28934585 | 1.00 | NLRP3 (0.49) | NLRP3KDM4EHSD17B10PDE5AALDH1A1 | |
| SCHEMBL28934592 | 1.00 | NLRP3 (0.49) | NLRP3KDM4EHSD17B10PDE5AALDH1A1 | |
| SCHEMBL30108709 | 0.88 | NLRP3 (0.46) | NLRP3PDE5AALDH1A1IRAK4KCNH2 | |
| SCHEMBL30108664 | 0.84 | NLRP3 (0.70) | NLRP3KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL28934508 | 0.84 | NLRP3 (0.70) | NLRP3KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL26435079 | 0.83 | NLRP3 (0.50) | NLRP3KDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL26435304 | 0.83 | IL1B (0.42) | NLRP3KDM4EHSD17B10PDE5AALDH1A1 | |
| SCHEMBL30108854 | 0.83 | NLRP3 (0.44) | NLRP3IRAK4 | |
| SCHEMBL28934427 | 0.81 | NLRP3 (0.47) | NLRP3KDM4EHSD17B10PDE5AALDH1A1 | |
| SCHEMBL28934430 | 0.81 | NLRP3 (0.47) | NLRP3KDM4EHSD17B10PDE5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDM4E 3867/4885HSD17B10 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.